Acute myeloid leukemia with mutated NPM1
MONDO:0044923An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.
Also known as: AML with mutated NPM1, AML, Mutation of the Nucleophosmin Gene, AML, NPM1 Mutation, AML, NPM1 gene mutation, AML, Nucleophosmin Gene Mutation, NPMc+ AML, acute myeloid leukaemia with cytoplasmic nucleophosmin, acute myeloid leukemia with cytoplasmic nucleophosmin
3116 clinical trials for this condition and its sub-types, 25 tagged with Acute myeloid leukemia with mutated NPM1 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Can a menin-blocking drug outsmart stubborn leukemia?
Disease control Not yet recruitingThis trial is testing an experimental drug called S243249, which blocks a protein called menin, in people whose acute leukemia has come back or not responded to standard treatment. The study focuses on patients with specific genetic changes (KMT2A or NUP98 translocations, or NPM1…
Phase 1/2 • Sponsor: Servier • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Disease control Not yet recruitingThis early-phase trial is testing a new personalized therapy called BSB-2002 for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses a patient's own immune cells (T cells) that are genetically modified to …
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo targets tough leukemia in early trial
Disease control Not yet recruitingThis early-phase study tests two oral drugs, ziftomenib and mezigdomide, given together to adolescents and adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial focuses on people whose leukemia has specific genetic changes (KMT2A rea…
Phase 1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC